Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Newcastle disease virus (NDV), a negative-sense RNA virus, exhibits oncolytic properties.
• Previous hypotheses suggested NDV's tumor specificity stemmed from impaired antiviral responses in cancer cells.
• The role of apoptosis resistance in NDV's selective tumor cell replication requires further elucidation.

Purpose of the Study:

• To investigate the underlying mechanism of NDV's oncolytic selectivity in tumor cells.
• To determine if NDV's tumor specificity is linked to apoptosis resistance rather than antiviral response.
• To explore the potential of NDV as an anticancer agent for chemoresistant tumors.

Main Methods:

• Utilized the human non-small-cell lung cancer cell line A549.
• Overexpressed the antiapoptotic protein Bcl-xL in A549 cells to assess its impact on NDV activity.
• Evaluated NDV replication, oncolytic activity, apoptosis induction, and type I interferon (IFN) response.

Main Results:

• NDV demonstrated oncolytic activity even in tumor cells with robust type I IFN responses.
• Oncolytic selectivity was dependent on tumor cell resistance to apoptosis, particularly enhanced by Bcl-xL overexpression.
• Bcl-xL-overexpressing cells showed enhanced viral replication, syncytium formation, and a paradoxical increase in apoptosis during later viral cycles.

Conclusions:

• Tumor cell resistance to apoptosis is a key factor in NDV's oncolytic specificity.
• NDV can effectively target cancer cells with enhanced antiapoptotic activity, including chemoresistant types.
• These findings highlight a novel mechanism for NDV's anticancer potential and its suitability for specific tumor microenvironments.